Portopulmonary hypertension history and symptoms: Difference between revisions
No edit summary |
Irfan Dotani (talk | contribs) No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Portopulmonary hypertension}} | {{Portopulmonary hypertension}} | ||
{{CMG}} | {{CMG}}; {{AE}} | ||
{{PleaseHelp}} | |||
==Overview== | ==Overview== | ||
==History and Symptoms== | |||
Once patients are symptomatic, they present with right heart [[dysfunction]] secondary to [[pulmonary hypertension]] and its consequent [[dyspnea]], fatigue, chest pain and [[syncope]].<ref> Martinex-Palli et al. Liver Transplant in High Risk Patients. Transplant Proceedings 2005;37:3861-3864</ref> Patients tend to have a poor cardiac status, with 60% having stage III-IV [[NYHA]] heart failure. | Once patients are symptomatic, they present with right heart [[dysfunction]] secondary to [[pulmonary hypertension]] and its consequent [[dyspnea]], fatigue, chest pain and [[syncope]].<ref> Martinex-Palli et al. Liver Transplant in High Risk Patients. Transplant Proceedings 2005;37:3861-3864</ref> Patients tend to have a poor cardiac status, with 60% having stage III-IV [[NYHA]] heart failure. | ||
PPH is actually independent of the severity of [[cirrhosis]] but may be more common in specific types of cirrhosis, in one series more so in [[Autoimmune Hepatitis]] and less in [[Hepatitis C]] cirrhosis,<ref name=Kawut>Kawut SM et al. Clinical Risk Factors for Portopulmonary Hypertension. Hepatology 2008;48</ref> while in another it was equally distributed throughout the diagnoses.<ref name=Tapper>Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc. 2009 Jun;41(5):1969-71.</ref>. | PPH is actually independent of the severity of [[cirrhosis]] but may be more common in specific types of cirrhosis, in one series more so in [[Autoimmune Hepatitis]] and less in [[Hepatitis C]] cirrhosis,<ref name=Kawut>Kawut SM et al. Clinical Risk Factors for Portopulmonary Hypertension. Hepatology 2008;48</ref> while in another it was equally distributed throughout the diagnoses.<ref name=Tapper>Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc. 2009 Jun;41(5):1969-71.</ref>. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
{{WS}} | |||
{{WH}} | |||
Latest revision as of 18:26, 18 July 2016
|
Portopulmonary hypertension Microchapters |
|
Differentiating Portopulmonary hypertension from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Portopulmonary hypertension history and symptoms On the Web |
|
American Roentgen Ray Society Images of Portopulmonary hypertension history and symptoms |
|
Portopulmonary hypertension history and symptoms in the news |
|
Directions to Hospitals Treating Portopulmonary hypertension |
|
Risk calculators and risk factors for Portopulmonary hypertension history and symptoms |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
History and Symptoms
Once patients are symptomatic, they present with right heart dysfunction secondary to pulmonary hypertension and its consequent dyspnea, fatigue, chest pain and syncope.[1] Patients tend to have a poor cardiac status, with 60% having stage III-IV NYHA heart failure.
PPH is actually independent of the severity of cirrhosis but may be more common in specific types of cirrhosis, in one series more so in Autoimmune Hepatitis and less in Hepatitis C cirrhosis,[2] while in another it was equally distributed throughout the diagnoses.[3].
References
- ↑ Martinex-Palli et al. Liver Transplant in High Risk Patients. Transplant Proceedings 2005;37:3861-3864
- ↑ Kawut SM et al. Clinical Risk Factors for Portopulmonary Hypertension. Hepatology 2008;48
- ↑ Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc. 2009 Jun;41(5):1969-71.